Trial · NCT00753675
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival | Arm A Vandetanib 300 mg | 105 | 95% Confidence Interval 72 to 155 | days | |
| Progression Free Survival | Arm B Vandetanib 100mg + Gemcitab | 114 | 95% Confidence Interval 91 to 193 | days | |
| Progression Free Survival | ARM C Placebo+ Gemcitabine | 148 | 95% Confidence Interval 72 to 225 | days | |
| Objective Tumor Response Rate (CR+PR), | Arm A Vandetanib 300 mg | Objective Response = NO | 54 | Participants | |
| Objective Tumor Response Rate (CR+PR), | Arm B Vandetanib 100mg + Gemcitab | Objective Response = NO | 46 | Participants | |
| Objective Tumor Response Rate (CR+PR), | ARM C Placebo+ Gemcitabine | Objective Response = NO | 45 | Participants | |
| Objective Tumor Response Rate (CR+PR), | Arm A Vandetanib 300 mg | Objective Response = YES | 2 | Participants | |
| Objective Tumor Response Rate (CR+PR), | Arm B Vandetanib 100mg + Gemcitab | Objective Response = YES | 11 | Participants | |
| Objective Tumor Response Rate (CR+PR), | ARM C Placebo+ Gemcitabine | Objective Response = YES | 7 | Participants | |
| Disease Control Rate (CR+PR+SD) | Arm A Vandetanib 300 mg | Disease control rate = NO | 42 | Partecipants | |
| Disease Control Rate (CR+PR+SD) | Arm B Vandetanib 100mg + Gemcitab | Disease control rate = NO | 40 | Partecipants | |
| Disease Control Rate (CR+PR+SD) | ARM C Placebo+ Gemcitabine | Disease control rate = NO | 32 | Partecipants | |
| Disease Control Rate (CR+PR+SD) | Arm A Vandetanib 300 mg | Disease control rate = YES | 14 | Partecipants | |
| Disease Control Rate (CR+PR+SD) | Arm B Vandetanib 100mg + Gemcitab | Disease control rate = YES | 17 | Partecipants | |
| Disease Control Rate (CR+PR+SD) | ARM C Placebo+ Gemcitabine | Disease control rate = YES | 20 | Partecipants | |
| Duration of Response (DOR) | Arm A Vandetanib 300 mg | 277 | 95% Confidence Interval 267 to 286 | Days | |
| Duration of Response (DOR) | Arm B Vandetanib 100mg + Gemcitab | 179 | 95% Confidence Interval 85 to 369 | Days | |
| Duration of Response (DOR) | ARM C Placebo+ Gemcitabine | 127 | 95% Confidence Interval 85 to 152 | Days | |
| Overall Survival | Arm A Vandetanib 300 mg | 228 | 95% Confidence Interval 190 to 364 | Days | |
| Overall Survival | Arm B Vandetanib 100mg + Gemcitab | 284 | 95% Confidence Interval 213 to 359 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00753675/results